US surpasses 1,000 measles cases for the 3rd time in 26 years, CDC data shows

Measles cases in the U.S. have reached 1,136 after 154 new cases in the past week, with infections confirmed in 27 states and a large South Carolina outbreak accounting for 979 cases. CDC data indicate about 92% of cases are among unvaccinated or vaccination-status-unknown individuals, 4% had one MMR dose and 4% had two; kindergarten MMR coverage fell to 92.5% in 2024-25 versus 95.2% in 2019-20. The resurgence, coming after 2,281 U.S. cases in 2023 (the highest in 33 years), presents localized public-health and policy risks that could affect healthcare providers, insurers and regionally exposed businesses.

Analysis

Market structure: Short, concentrated winners are vaccine manufacturers (Merck - MRK) and diagnostics/lab services (Quest Diagnostics - DGX; Laboratory Corp - LH) from incremental MMR revs and testing volume; telehealth (TDOC) gets modest consult upside. Losses are localized: regional childcare, K-12 services and discretionary travel in high-outbreak states (airline ETF JETS, regional hotel REITs) face transient demand hit. Expect volume-driven revenue bumps of low single-digits for MRK/DGX over 1–3 quarters, but limited pricing power given established vaccine contracts.

Risk assessment: Tail risks include a sustained national surge (>2,000 cases, >40 states) that triggers emergency funding, school closures, or litigation against providers; very low probability but high policy impact. Immediate (days) risks are localized operational disruptions; short-term (weeks–months) see spikes in orders and supply-chain strain (vials, cold chain); long-term (quarters–years) could shift public health funding and mandate regimes. Hidden dependencies: social-media-driven vaccine hesitancy and state-level regulatory responses will drive demand volatility.

Trade implications: Favor small, tactical healthcare longs: 1–2% positions in MRK and 1% each in DGX/LH, with 3–6 month call spreads to cap capital and target delivery-season upside. Pair trade: long DGX, short JETS (0.5% each) to capture diagnostics tailwind vs localized travel weakness. Entry window: deploy within 2–6 weeks (before school immunization push); trim or exit after 3–6 months or if CDC weekly new-case run rate falls below 50/week for 4 consecutive weeks.

Contrarian angles: Consensus underestimates diagnostics and lab-services revenue capture and overestimates systemic market disruption; 2019 parallel shows vaccine demand spikes add volume but not margin, so pure-play vaccine longs should be sized small. Beware an overdone sell-off in regional travel; if CDC metrics breach 200 new cases/week for 4 weeks, rotate +2x into healthcare positions and cut discretionary exposure immediately.

Key Decisions for Investors

• Establish a 1.5% long position in Merck (MRK) to capture incremental MMR demand; hedge with a 3–6 month call spread (buy near-the-money, sell 10–15% OTM) to limit capital and target upside if cases remain elevated over 3 months.
• Allocate 1% each to Quest Diagnostics (DGX) and Laboratory Corp (LH) long positions to capture testing volume; use 3–6 month out-of-the-money call spreads sized at one-third of the equity position to leverage upside around school vaccination season.
• Implement a 0.5% pair trade: long DGX vs short the U.S. Airlines ETF (JETS) 0.5% to profit from diagnostics upside and localized travel weakness; rebalance if JETS underperforms by >10% or DGX outperforms by >15% within 90 days.
• Reduce exposure to regional travel/hospitality (top holdings in affected-state municipal revenue and regional hotel REITs) by 1–2% if CDC weekly new-case additions exceed 200 for 3 consecutive weeks; restore if cases drop below 50/week for 4 straight weeks.
• Monitor CDC weekly case releases and state vaccine order announcements as catalysts; if national cases exceed 2,000 or spread to >40 states, increase healthcare/vector positions (MRK/DGX/LH) by another 1–2% within 7 trading days to capture policy-driven funding and procurement ramps.